Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Subscribe
Login
Password
Password
Remember me
Forgot password?
Close login form
Home
Iksuda Therapeutics
Iksuda Therapeutics
Activities:
Research & Development
Pharmaceutical
Trending Articles
EVA Pharma joins forces with DNA Script and Quantoom to bring end-to-end mRNA manufacturing to Egypt
The European and African partners plan to develop the first end-to-end, sterile GMP mRNA vaccine and therapeutic production platform in Egypt, bolstering the country's presence...
Neopac becomes the first tube manufacturer to pass the RecyClass EN 15343 audit
The EN 15343 certification regulates the use of recycled materials in plastic packaging, ensuring products are traceable, sustainable and of a high quality
Serum Institute of India collaborates with Univercells to enhance availability of affordable personalised oncology
The partnership endeavours to speed up development times and distribute personalised cancer vaccines to all locations globally, rather than just economically developed countries
PSL Process Solutions in a new 3D virtual environment
The latest innovation provides a dynamic new way for customers to interact with equipment through an immersive Virtual Environment comprising 3D and augmented reality (AR)...
BioMed X and Merck successfully complete ecDNA oncology research programme
The project looked at which genes impact the prevalence of extrachromosomal DNA in cancer cells, and how ecDNA influences the adaptability of these cells
Upcoming event
Pharma Packaging and Labelling Forum
5–6 March 2025 | Conference | San Diego, US
See all
Related Content
Research & Development
LegoChem and Iksuda expand ADC license agreement
In April 2020, Iksuda licensed global development and commercialisation rights for three ADC programmes using LCB's ADC linker/toxin platform
Finance
ADC developer Iksuda Therapeutics closes $47m financing round
The company’s lead preclinical candidate, IKS03, is a CD19-targeted ADC candidate for B-cell cancers
Research & Development
Iksuda releases first data on ADC efficacy on tumour regression
British next-gen Antibody Drug Conjugates developer says its IKS01 allows for the targeted delivery of a potent cytotoxic payload to tumours
Pharmaceutical
Iksuda and Femtogenix ink solid tumour agreement
Iksuda has stated it will use Femtogenix payload molecules to progress its lead antibody drug conjugate
Media
Glythera announces corporate name change and rebranding
Now the primary focus of Iksuda Therapeutics will be on the development of superior ADCs for treatment of difficult-to-treat cancers
Ingredients
Glythera appoints Professor Kerry Chester to SAB
Recruitment
Glythera appoints Chief Scientific Officer and strengthens SAB
Subscribe now